Markets

GSK Commences Tender Offer To Acquire Nuvalent For $124 Per Share

June 24, 2026 — 11:04 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - GSK plc (GSK) said Wednesday that its indirect wholly-owned subsidiary, Harmony Row Acquisition Co., has commenced a tender offer to acquire all outstanding shares of Nuvalent Inc. (NUVL) for $124.00 per share in cash.

The tender offer is being made under the merger agreement announced on June 9, 2026. Following completion of the offer and satisfaction of customary conditions, Harmony Row Acquisition Co. will merge with Nuvalent, making the biotechnology company a direct wholly-owned subsidiary of GSK LLC.

Nuvalent's Board of Directors has unanimously recommended that shareholders accept the offer and tender their shares.

Nuvalent is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The acquisition is expected to strengthen GSK's oncology pipeline and precision medicine capabilities.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
GSK

Latest Articles
Data is currently not available